Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Metadata
Title
Amlodipine versus Diltiazem CR in the Reduction of the Total Ischemic Burden: The Circadian Anti-Ischemia Program in Europe (CAPE) II Trial — Clinical Rationale and Methodology
Author
John E. Deanfield
Publication date
01-10-1998
Publisher
Kluwer Academic Publishers
Published in
Cardiovascular Drugs and Therapy / Issue Special Issue 3/1998
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1023/A:1007769808941

Other articles of this Special Issue 3/1998

Cardiovascular Drugs and Therapy 3/1998 Go to the issue

OriginalPaper

Management of Ischemic Heart Disease: Therapeutic Options and Future Directions Official Satellite Symposium to the XVIIth Congress of the European Society of Cardiology

OriginalPaper

A Comparative Study of Once-Daily Amlodipine versus Twice-Daily Diltiazem Controlled Release (CR) in the Treatment of Stable Angina Pectoris

OriginalPaper

Angina Pectoris in a Contemporary Population: Characteristics and Therapeutic Implications

OriginalPaper

Management of Ischemic Heart Disease: Therapeutic Options and Future Directions–Official Satellite Symposium to the XVIIth Congress of the European Society of Cardiology

OriginalPaper

Treatment of Chronic Myocardial Ischemia: Rationale and Treatment Options

OriginalPaper

Therapeutic Options and Cost Considerations in the Treatment of Ischemic Heart Disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits